Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Alx Oncology Holdings (ALXO) Return on Sales (2019 - 2023)

Alx Oncology Holdings' Return on Sales history spans 5 years, with the latest figure at 219.44% for Q4 2023.

  • For Q4 2023, Return on Sales fell 35209.0% year-over-year to 219.44%; the TTM value through Dec 2023 reached 15.77%, down 50270.0%, while the annual FY2025 figure was 0.31%, 7768.0% down from the prior year.
  • Return on Sales for Q4 2023 was 219.44% at Alx Oncology Holdings, down from 130.41% in the prior quarter.
  • Across five years, Return on Sales topped out at 17656.5% in Q3 2022 and bottomed at 219.44% in Q4 2023.
  • The 5-year median for Return on Sales is 37.91% (2023), against an average of 3024.57%.
  • The largest annual shift saw Return on Sales skyrocketed 826042bps in 2022 before it tumbled -1752609bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 2.42% in 2019, then crashed by -1170bps to 30.7% in 2020, then crashed by -178bps to 85.42% in 2021, then soared by 255bps to 132.65% in 2022, then crashed by -265bps to 219.44% in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Return on Sales are 219.44% (Q4 2023), 130.41% (Q3 2023), and 92.7% (Q2 2023).